Full-Life Technologies Limited is a fully integrated global radiotherapeutics company headquartered in Shanghai, China with operations in Europe.
Total raised: $47.3M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.01.2024 | Series B | $47.3M | - |
Mentions in press and media 18
| Date | Title | Description |
| 06.08.2024 | Latest Updates of Viva Biotech's Portfolio Companies | HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies ... |
| 17.07.2024 | Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors | Full-Life Technologies seals $571.5 million agreement with SK Biopharmaceuticals to license and further develop Full-Life's 'FL-091' radiopharmaceutical compound into an innovative anti-cancer treatment for worldwide markets HEIDELBERG, Ger... |
| 16.07.2024 | Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors | Full-Life Technologies seals $571.5 million agreement with SK Biopharmaceuticals to license and further develop Full-Life's 'FL-091' radiopharmaceutical compound into an innovative anti-cancer treatment for worldwide markets HEIDELBERG, Ger... |
| 02.07.2024 | Full-Life Technologies Granted FDA Fast Track Designation for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer | HEIDELBERG, Germany, July 2, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation f... |
| 11.06.2024 | Full-Life Technologies Disclosed Preclinical Data of its NTSR1-targeting RDC Program FL-091 in an Oral Presentation at the 2024 SNMMI Annual Meeting | SHANGHAI and HEIDELBERG, Germany, June 11, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, released preclinical data of its NTSR1-targeting RDC program FL-091 in an oral presenta... |
| 10.06.2024 | Full-Life Technologies Disclosed Preclinical Data of its NTSR1-targeting RDC Program FL-091 in an Oral Presentation at the 2024 SNMMI Annual Meeting | SHANGHAI and HEIDELBERG, Germany, June 10, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, released preclinical data of its NTSR1-targeting RDC program FL-091 in an oral presenta... |
| 29.05.2024 | Full-Life Technologies Announces Clearance from FDA of IND Application for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer | HEIDELBERG, Germany , May 29, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced it has received clearance of its Investigational New Drug (IND) Application from the... |
| 16.05.2024 | Full-Life Technologies Announces Appointment of Mark S. de Jong, PhD, as Chief Technical Officer | GEMBLOUX, Belgium, May 16, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the appointment of Mark S. de Jong, PhD, to the newly created position of Chief Technic... |
| 26.03.2024 | Full-Life Technologies Achieves Regulatory Milestone with Nuclear Permit, Advancing Radioisotope Facility Construction | GEMBLOUX, Belgium, March 26, 2024 /PRNewswire/ -- Full-Life Technologies ("Full-Life"), today announced the recent achievement of its subsidiary "Full-Life Technology Europe" has obtained a Nuclear Permit for a class IIA... |
| 05.01.2024 | Deals in brief: Mixue Bingcheng and GoodMe apply for Hong Kong IPO, UniFAHS and Silicon Box secure funding, 11 China deals, and more | Chinese bubble tea brands Mixue Bingcheng and GoodMe file prospectuses for Hong Kong IPO Mixue Bingcheng and GoodMe, two of China’s major bubble tea brands, filed prospectuses for Hong Kong listings on January 2, 2024, with the aim of bolst... |
Show more